



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

JUN 22 2011

Re: VIIBRYD  
Patent Nos. 5,532,241 and 7,834,020  
Docket Nos. FDA-2011-E-0389  
FDA-2011-E-0380

The Honorable David J. Kappos  
Under Secretary of Commerce for Intellectual Property  
Director of the United States Patent and Trademark Office  
Mail Stop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the applications for patent term extension for U.S. Patent Nos. 5,532,241 and 7,834,020 filed by Merck Patent GmbH, under 35 U.S.C. § 156. The human drug product claimed by the patents is VIIBRYD (vilazodone hydrochloride), which was assigned new drug application (NDA) No. 22-567.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The NDA was approved on January 21, 2011, which makes the submission of the patent term extension applications on March 17, 2011, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

Kappos - Viibryd  
Patent Nos. 5,532,241 and 7,834,020  
Page 2

cc: Danielle L. Herritt  
McCarter & English LLP  
265 Franklin Street  
Boston, MA 02110